Valeant Pharmaceuticals International, Inc. (VRX) belonging to the Medical sector has declined -1.52% and closed its last trading session at $11.03.
The company reported its EPS on 02/28/2017. Currently, the stock has a 1 Year Price Target of $19.74.
The consensus recommendation, according to Zacks Investment research, is 3.14. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 3.14 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 3.14 and 2.89 respectively.
Valeant Pharmaceuticals International, Inc. on 02/28/2017 reported its EPS as $1.26 with the analysts projecting the EPS of the stock as $1.21. The company beat the analyst EPS Estimate with the difference of $0.05. This shows a surprise factor of 4.1%.
Many analysts have provided their estimated foresights on Valeant Pharmaceuticals International, Inc. Earnings, with 15 analysts believing the company would generate an Average Estimate of $0.91.
Whereas they predicted High and Low Earnings Estimate as $1.32 and $0.38 respectively. While in the same Quarter Previous year, the Actual EPS was $1.27.
Analysts are also projecting an Average Revenue Estimate for Valeant Pharmaceuticals International, Inc. as $2.17 Billion in the Current Quarter. This estimate is provided by 12 analysts.
The High Revenue estimate is predicted as 2.24 Billion, while the Low Revenue Estimate prediction stands at 2.06 Billion. The company’s last year sales total was 2.37 Billion.
For the Current Quarter, the growth estimate for Valeant Pharmaceuticals International, Inc. is -28.3%, while for the Next Quarter the stock growth estimate is -32.1%.
In the past 5 years, the stock showed growth of 12.66% per annum. While for the next 5 years, the growth estimate is 12.95%.
The Company got Downgrade by Morgan Stanley on 15-Dec-16 from Overweight to Equal-Weight.
Over the period of 6 months, Insider Purchases show a total of 6 transaction in which 30775 shares were traded. 3 Insider Sales transactions were made totaling 4328940 shares traded.
17 analysts projected Price Targets for Valeant Pharmaceuticals International, Inc.. The analysts believe that the company stock price could grow as high as $55. The Low Price target projection by analysts is $8 and the Mean Price Target is $19.74.
Valeant Pharmaceuticals International, Inc. (VRX) has the market capitalization of $3.76 Billion. The company rocked its 52-Week High of $38.5 on May 3, 2016 and touched its 52-Week Low of $10.5 on Mar 14, 2017.
The stock has Return on Assets (ROA) of -5.2 percent. Return on Equity (ROE) stands at -52.7% and Return on Investment (ROI) of -1.6 percent.
The stock is currently showing YTD performance of -24.04 Percent. The company has Beta Value of -0.2 and ATR value of 0.79. The Weekly and Monthly Volatility stands at 5.13% and 5.80%.